Novo Nordisk is seeking up to US$830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...
In this review, GlobalData considers the products both approved and priced in 2024 and the factors that influenced their ...
In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr.
Ascendis Pharma (NASDAQ:ASND) reported a fourth-quarter EPS loss of 64 cents, beating the consensus loss of 1.07 euros. Total ...
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Hims & Hers Health (HIMS) stock hits an all-time high as the company's controversial Super Bowl ad is set to air this Sunday ...
On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting a profit of $22.86 per share, according to data compiled by LSEG.
Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo Nordisk predicted growth will slow this year. The Danish pharmaceutical company has ...